22:42 , May 15, 2019 |  BC Extra  |  Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
23:29 , May 3, 2019 |  BioCentury  |  Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One...
21:28 , May 2, 2019 |  BC Extra  |  Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

Label expansion in AML for Agios’ Tibsovo  FDA approved an sNDA for Tibsovo ivosidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as monotherapy for adults with newly diagnosed acute myelogenous leukemia (AML) with a susceptible isocitrate dehydrogenase...
21:58 , Apr 26, 2019 |  BioCentury  |  Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
18:37 , Apr 4, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
23:37 , Mar 26, 2019 |  BC Extra  |  Company News

Management tracks: Rubius, Abingworth, Arcus

Rubius hired Greg Whitehead as SVP and chief quality officer, a newly created position. He was VP, quality at bluebird bio Inc. (NASDAQ:BLUE). Whitehead will be responsible for defining the company's quality strategy to meet...
23:47 , Mar 4, 2019 |  BC Extra  |  Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...
02:40 , Feb 28, 2019 |  BC Week In Review  |  Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange Feb. 25, raising HK$2.2 billion (US$285 million). The oncology company rose HK$0.86 to HK$12.86 in its first day of trading Feb....
15:01 , Feb 26, 2019 |  BC Extra  |  Financial News

First-day gain for CStone on Hong Kong exchange

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) rose HK$0.86 to HK$12.86 in its first day of trading Tuesday after raising HK$2.2 billion ($285 million) in its IPO. The oncology company priced the offering early Monday near the...
05:32 , Feb 25, 2019 |  BC Extra  |  Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange early Monday, raising HK$2.2 billion (US$285 million). The offering values CStone at HK$11.8 billion (US$1.5 billion). CStone sold 18.6 million shares...